Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Sarcoma 2Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma 1Ovarian Neoplasms 1Neurofibrosarcoma 1Malignant mesenchymal tumor 1Liposarcoma, Myxoid 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Fibrosarcoma 1

Interventions

Paclitaxel 35Carboplatin 35Bevacizumab 14olaparib 13niraparib 11apatinib 11Gemcitabine 10liposomal doxorubicin 9Hyperthermic Intraperitoneal Chemotherapy 9Cisplatin 9pembrolizumab 8Cyclophosphamide 8fludarabine 7Etoposide 7Topotecan 6fluzoparib 5Surveys and Questionnaires 5Drug Therapy 5Albumin-Bound Paclitaxel 5anlotinib 4Immunohistochemistry 4Ifosfamide 4Doxorubicin 4Docetaxel 4Cytoreduction Surgical Procedures 4Taxes 3Surgical Procedures, Operative 3Poly(ADP-ribose) Polymerase Inhibitors 3Neoadjuvant Therapy 3Laparoscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Ovarian Neoplasms × brostallicin × Clear all
NCT00410462 2014-08-08

Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Unknown
118 enrolled
GynecologicSarcoma

Malignant mesenchymal tumor, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Ovarian Neoplasms, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡